Drug Interactions between Caprelsa and Tepmetko
This report displays the potential drug interactions for the following 2 drugs:
- Caprelsa (vandetanib)
- Tepmetko (tepotinib)
Interactions between your drugs
No interactions were found between Caprelsa and Tepmetko. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Caprelsa
A total of 313 drugs are known to interact with Caprelsa.
- Caprelsa is in the following drug classes: EGFR inhibitors, multikinase inhibitors, VEGF/VEGFR inhibitors.
- Caprelsa is used to treat Thyroid Cancer.
Tepmetko
A total of 260 drugs are known to interact with Tepmetko.
- Tepmetko is in the drug class multikinase inhibitors.
- Tepmetko is used to treat Non Small Cell Lung Cancer.
Drug and food interactions
tepotinib food
Applies to: Tepmetko (tepotinib)
ADJUST DOSING INTERVAL: Food enhances the oral bioavailability of tepotinib. When tepotinib was administered after a high-fat, high-calorie meal (approximately 800 to 1000 calories; 150 calories from protein, 250 calories from carbohydrate, 500 to 600 calories from fat), tepotinib peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 2-fold and 1.6-fold, respectively, compared to administration under fasted conditions.
MANAGEMENT: Tepotinib should be administered with food at approximately the same time each day.
References
- (2021) "Product Information. Tepmetko (tepotinib)." EMD Serono Inc
Therapeutic duplication warnings
Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.
Multikinase inhibitors
Therapeutic duplication
The recommended maximum number of medicines in the 'multikinase inhibitors' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'multikinase inhibitors' category:
- Caprelsa (vandetanib)
- Tepmetko (tepotinib)
Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.
See also
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.